Galderma News & Analysis

Galderma Reports Nearly 25% Growth Amid Botox Demand Increase

CEO Flemming Ørnskov announced that Galderma has seen nearly 25% sales growth year-on-year at constant currencies, attributed to the rising use of GLP-1 weight-loss drugs like Ozempic. Approximately one in 10 U.S. adults are now using these medications, creating strong demand for Galderma’s aesthetic products to combat facial volume loss associated with significant weight loss, informally known as 'Ozempic face.' Growth in the U.S. market was particularly notable at 32%, compared to 19% worldwide. This trend in increasing demand for cosmetic injectables may impact Galderma's market presence positively moving forward.